North America Contraceptives Market - Segmented by Contraceptive Methods, Mode of Delivery, Type of devices, by Gender and by Geography - Growth, Trends and Forecasts (2017 - 2022)

The North American market for contraceptives is estimated to be worth USD 1.35 billion in the year 2014. This market is expected to reach USD 1.97 billion by the end of 2019. During this period, the CAGR is projected to be 7.82%.

North America Contraceptives Market-Market Dynamics

The report details several factors driving and restraining the North American market for contraceptives. Some of these are discussed below.


A major factor contributing to the growth of the North American contraceptives market is the need to reduce the unwanted pregnancies happening in the USA and Canada. It is estimated that around 70% of the women who engage in sexual activities do not want to get pregnant. But the percentage population getting pregnant is not the same. The rising number of government initiatives to prevent unwanted pregnancies have been important in increasing the market growth. Some governments even issue contraceptives through public funding. These initiatives are propelling the market growth. Product innovation has also been a good driving factor for the growth of the market. It is observed that 6% of the North American population use contraceptives mainly to avail non-contraceptive health benefits.


Factors such as fear of side effects due to the use of contraceptives have been a drawback hindering the growth of the market. Economic constraints such as cost related issues and affordability issues have been major challenges for the market growth. Also, in certain cases, cultural and religious constraints have been holding back the market growth.

From the geographical point of view, the USA is the biggest market in the North American region. Following the USA is Canada, which is the second largest market. Over 80% of the women in the USA use the pill. It is observed that the use of implant contraceptives results in greater contraceptive effectiveness compared to all other methods.

The North American market for contraceptives can be segmented on the basis of the contraceptive method used, the mode of delivery of the contraceptive, the type of contraceptive device, gender, and geography.

Some of the key players in the market are:

Bayer Healthcare

Merck & Co.

Mylan Laboratories


The Female Health Company

What the Report Offers

Market definition for the North American contraceptive drugs & devices market along with identification of key drivers and restraints for the market.

Market analysis for the North American contraceptive drugs & devices market, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

An exhaustive understanding of the North American market for contraceptives.

A comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

An ideal opportunity for industry consultants and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

Wide-ranging information provided about the leading market players and the major strategies adopted by them.

1. Introduction

1.1 Report Description

1.2 Research Methodology

1.3 Major Stakeholders

2. Executive Summary

2.1 Key Findings

2.2 Market Overview

3. Market Overview

3.1 Market Definition

3.1.1 Introduction

3.2 Market Drivers

3.2.1 Product Innovation

3.2.2 Increasing incidence of STD's

3.2.3 Pregnancy prevention

3.2.4 Immediate Health benefits other than birth control

3.2.5 Rise in Government initiatives to prevent unwanted abortions and pregnancies

3.2.6 Rapid increase in global population

3.3 Market Restraints

3.3.1 Fear or experience of side effects

3.3.2 Cultural or Religious opposition

3.3.3 Limited access to contraception

3.3.4 Infertility issues

3.3.5 Economic constraints

3.4 Market opportunities

3.4.1 New product pipelines

3.4.2 Male Contraceptive Drugs

3.5 Porter's Five Force Analysis

3.5.1 Threat of a new entrant

3.5.2 Internal Rivalry

3.5.3 Buyer Bargaining Power

3.5.4 Supplier Bargaining Power

3.5.5 Threat of substitutes

4. Market Segmentation- North America Market for Contraceptive Drugs and Devices

4.1 Segmentation by Contraceptive Method

4.1.1 Sterilization

4.1.2 Pills

4.1.3 Implants

4.1.4 Injectables

4.1.5 Intrauterine Device (IUD)

4.1.6 Male Condoms

4.1.7 Vaginal barrier methods

4.1.8 Others

4.2 Segmentation by Mode of Delivery

4.2.1 Oral Contraceptives

4.2.2 Topical Contraceptives

4.2.3 Contraceptive Injectables

4.3 Segmentation by type of device

4.3.1 Condoms

4.3.2 Diaphragms

4.3.3 Cervical Caps

4.3.4 Sponges

4.3.5 Vaginal Rings

4.3.6 IUD

4.3.7 Implants

4.4 Segmentation by Gender

4.4.1 Male

4.4.2 Female

4.5 Segmentation by Geography

4.5.1 North America USA Canada Mexico

5. Competitive Landscape

5.1 Mergers & Acquisitions

5.2 New Product Launches

5.3 Agreements, Collaborations & Partnerships

5.4 Market Chain Analysis

5.5 Price Share Analysis

5.6 Recommendations for New market players

5.7 Recommendations for Existing market players

6. Company Profiles

6.1 Bayer Healthcare

6.1.1 Overview

6.1.2 Major Products and Services

6.1.3 Financials

6.1.4 Recent Developments

6.2 Pfizer

6.2.1 Overview

6.2.2 Major Products and Services

6.2.3 Financials

6.2.4 Recent Developments

6.3 Merck & Co.

6.3.1 Overview

6.3.2 Major Products and Services

6.3.3 Financials

6.3.4 Recent Developments

6.4 Teva Pharmaceuticals, Ltd.

6.4.1 Overview

6.4.2 Major Products and Services

6.4.3 Financials

6.4.4 Recent Developments

6.5 Agile Therapeutics

6.5.1 Overview

6.5.2 Major Products and Services

6.5.3 Financials

6.5.4 Recent Developments

6.6 Actavis PLC

6.6.1 Overview

6.6.2 Major Products and Services

6.6.3 Financials

6.6.4 Recent Developments

6.7 ANI Pharmaceuticals, Inc.

6.7.1 Overview

6.7.2 Major Products and Services

6.7.3 Financials

6.7.4 Recent Developments

6.8 Church & Dwight, Co. Inc.

6.8.1 Overview

6.8.2 Major Products and Services

6.8.3 Financials

6.8.4 Recent Developments

6.9 Fuji Latex Co., Ltd

6.9.1 Overview

6.9.2 Major Products and Services

6.9.3 Financials

6.9.4 Recent Developments

6.10 Johnson & Johnson, Ltd

6.10.1 Overview

6.10.2 Major Products and Services

6.10.3 Financials

6.10.4 Recent Developments

6.11 Lupin Pharmaceuticals, Ltd

6.11.1 Overview

6.11.2 Major Products and Services

6.11.3 Financials

6.11.4 Recent Developments

6.12 Okamato Industries, Inc.

6.12.1 Overview

6.12.2 Major Products and Services

6.12.3 Financials

6.12.4 Recent Developments

6.13 Reckitt Benckiser Group, PLC

6.13.1 Overview

6.13.2 Major Products and Services

6.13.3 Financials

6.13.4 Recent Developments

6.14 The Female Health Company

6.14.1 Overview

6.14.2 Major Products and Services

6.14.3 Financials

6.14.4 Recent Developments

6.15 Mylan Laboratories

6.15.1 Overview

6.15.2 Major Products and Services

6.15.3 Financials

6.15.4 Recent Developments

7. Appendix

7.1 Abbreviations

7.2 Sources

7.3 Bibliography

7.4 Disclaimer

Content are not available

Choose License Type